Sobi™ Appoints Paula Treutiger as Head of Communications and Investor Relations
STOCKHOLM, Nov. 19, 2018 /PRNewswire/ --Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Paula Treutiger as Head of Communications and Investor Relations. Paula will join Sobi on 1 January 2019 and be part of Sobi's Executive Committee.
Paula joins Sobi from Medicover, an international healthcare and diagnostic services provider listed on Nasdaq Stockholm, where she serves as Director Corporate Communication & Investor Relations. Paula brings more than 10 years of experience from Investor Relations and Communication in the healthcare industry from Meda and Gambro, and experience as an analyst of the pharma and medtech sector at Swedbank Robur, Alfred Berg and Carnegie. She has extensive experience in corporate and financial communication regarding acquisitions. She holds a Bachelor of Science in Business Administration and Economics from Stockholm University.
"As the largest Sweden-based pharmaceutical company listed on Nasdaq Stockholm, our growth in the European financial market has been substantial over the past years. Paula has an excellent network and knowledge of the field and we look forward to expand and further develop our relations with investors and the financial community under her leadership," says Guido Oelkers, CEO at Sobi.
Paula says she is excited to join Sobi. "Sobi is in a very exciting position with an ambition to grow into a global leader within rare diseases. Such a strategy requires direct and transparent communication to shape a clear future for employees, partners, shareholders and the financial community. I look forward to working with the organisation to make sure that everyone knows and understand Sobi's vision and the work we do to transform lives of people with rare diseases," she says.
Sobi™ is an international biopharmaceutical company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that transform lives for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.
For more information please contact
Charlotte af Klercker, Head of Communications (acting)
Jörgen Winroth, Vice President, Head of Investor Relations